

ABSTRACT

UTILIZATION OF INTERFERON ALPHA 5 IN THE TREATMENT OF VIRAL HEPATOPATHIES.

5

The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFN $\alpha$ 5 in the livers of patients with hepatitis C in comparison to healthy livers.

10 The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFN $\alpha$ 5. These significant differences

15 between the expression patterns of some livers and others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and

20 processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.

1

*Ar*

PCT

ORGANIZACION MUNDIAL DE LA PROPIEDAD INTELECTUAL  
Oficina Internacional

SOLICITUD INTERNACIONAL PUBLICADA EN VIRTUD DEL TRATADO DE COOPERACION  
EN MATERIA DE PATENTES (PCT)

(51) Clasificación Internacional de Patentes <sup>6</sup> : A61K 38/21	A1	(11) Número de publicación internacional: WO 99/58143
		(43) Fecha de publicación internacional: 18 de Noviembre de 1999 (18.11.99)

(21) Solicitud internacional: PCT/ES99/00134

(22) Fecha de la presentación internacional:  
13 de Mayo de 1999 (13.05.99)(30) Datos relativos a la prioridad:  
P 9801003 13 de Mayo de 1998 (13.05.98) ES(71) Solicitante (para todos los Estados designados salvo US):  
INSTITUTO CIENTIFICO Y TECNOLOGICO DE  
NAVARRA, S.A. [ES/ES]; Avenida Pío XII, 53, E-31008  
Pamplona (ES).

(72) Inventores; e

(75) Inventores/solicitantes (sólo US): PRIETO VALTUEÑA,  
Jesús [ES/ES]; Tudela, 22 - 4º, E-31002 Pamplona (ES).  
CIVEIRA MURILLO, Mª Pilar [ES/ES]; Irúnlarrea, 35  
- 1º, E-31008 Pamplona (ES). LARREA LEOZ, Esther  
[ES/ES]; Avenida Sancho el Fuerte, 34 - 3º C, E-31008  
Pamplona (ES).(74) Mandatario: DE ELZABURU, Alberto; Miguel Angel, 21,  
E-28010 Madrid (ES).(81) Estados designados: AE, AL, AM, AT, AU, AZ, BA, BE, BG,  
BK, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB,  
GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU,  
ZA, ZW, Patente ARIPO (GH, GM, KE, LS, MW, SD, SL,  
SZ, UG, ZW), Patente euroasiática (AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM), Patente europea (AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE),  
Patente OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GW,  
ML, MR, NE, SN, TD, TG).

Publicada


Con informe de búsqueda internacional.

(54) Title: UTILIZATION OF INTERFERON ALPHA 5 IN THE TREATMENT OF VIRAL HEPATOPATHIES

(54) Título: USO DEL INTERFERON ALFA 5 EN EL TRATAMIENTO DE LAS HEPATOPATIAS VIRALES

(57) Abstract

The invention relates to the use of the interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFN $\alpha$ 5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the sub-type alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFN $\alpha$ 5. These significant differences between the expression patterns of some livers and others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.



BEST AVAILABLE COPY